Pharmakotherapie von hereditären Netzhautdystrophien
- PMID: 40127652
- DOI: 10.1055/a-2511-6878
Pharmakotherapie von hereditären Netzhautdystrophien
Conflict of interest statement
Katarina Stingl: Katarina Stingl is/was consultant for Novartis, ProQR Therapeutics, ViGeneron, Santen, Janssen, Lundbeck, THEA Laboratories with all fees paid to University of Tuebingen to support research. No conflict of interests for this manuscript.Claudia Priglinger declare that she has no conflict of interest.
LinkOut - more resources
Full Text Sources
